Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
NCT00538343 · Biogen · PHASE2 · terminated · last registry update 2025-05-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business Decision” | – | Registry record, Biogen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-22Phase 3 first posted: Genmab, Rina-S + Paclitaxel (NCT07604766)
- 2026-05-04Phase 3 first posted: Genmab, Rina-S + Bevacizumab (NCT07564141)
- 2026-04-22Phase 3 first posted: Boehringer Ingelheim, Obrixtamig + Carboplatin (NCT07544654)
- 2026-04-22Phase 3 first posted: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc, Investigator's choice of Chemotherapy + Azenosertib (NCT07546500)
- 2026-04-08Results posted on the registry: ECOG-ACRIN Cancer Research Group, Capecitabine + Carboplatin (NCT02595424)
- 2026-03-30Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-B01D1 + Tislelizumab (NCT07502300)
- 2026-03-30Results posted on the registry: Medical College of Wisconsin, Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen + Cladribine and Cytarabine (CLLDAC) Regimen (NCT03150004)
- 2026-03-16Phase 3 first posted: Boehringer Ingelheim, obrixtamig + atezolizumab (NCT07472517)
- 2026-01-26Phase 3 first posted: AbbVie, ABBV-706 + Topotecan (NCT07365241)
- 2026-01-14Results posted on the registry: Alliance for Clinical Trials in Oncology, carmustine + cytarabine (NCT01511562)
- 2025-12-29Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Lurbinectedin (NCT05091567)
- 2025-12-22Phase 3 first posted: Bambino Gesù Hospital and Research Institute, Ruxolitinib + Blinatumomab (NCT07297914)
- 2025-12-18Phase 3 first posted: Nationwide Children's Hospital, Bridging Chemotherapy + Induction Cycles A1-A3 (NCT07291102)
- 2025-12-16Phase 3 first posted: GlaxoSmithKline, Mocertatug rezetecan + Paclitaxel (NCT07286331)
- 2025-12-16Phase 3 first posted: GlaxoSmithKline, Mocertatug rezetecan + Paclitaxel (NCT07286266)
- 2025-12-01Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M11D1 + Cytarabine (NCT07255872)
- 2025-11-03Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Bleximenib + Cytarabine (NCT07223814)
- 2025-10-29Results posted on the registry: Hoffmann-La Roche, Tiragolumab + Atezolizumab (NCT04665856)
- 2025-10-23Phase 3 first posted: SWOG Cancer Research Network, Cyclophosphamide + Doxorubicin Hydrochloride (NCT07220187)
- 2025-10-20Phase 3 first posted: Zai Lab (Shanghai) Co., Ltd., ZL-1310 + Investigator's Choice of Therapy (NCT07218146)
- 2025-10-10Phase 3 first posted: AstraZeneca, AZD0486 + R-mini-CHOP (NCT07215585)
- 2025-10-09Phase 3 first posted: Eli Lilly and Company, Sofetabart Mipitecan + Paclitaxel (NCT07213804)
- 2025-10-09Phase 3 first posted: Incyte Corporation, INCB123667 + Investigator's choice of chemotherapy (NCT07214779)
- 2025-10-08Phase 3 first posted: Syndax Pharmaceuticals, Revumenib + Placebo (NCT07211958)
- 2025-09-22Results posted on the registry: St. Jude Children's Research Hospital, Venetoclax + Navitoclax (NCT05192889)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision